Hypoxia-targeting by tirapazamine (TPZ) induces preferential growth inhibition of nasopharyngeal carcinoma cells with Chk1/2 activation

Investigational New Drugs

Volumn 29, Issue 3, 2011, Pages 401-410

  Hong, Bo ^a   Lui, Vivian W Y ^a   Hui, Edwin P ^a   Ng, Margaret H L ^a   Cheng, Suk Hang ^a   Sung, Fion L ^a   Tsang, Chi Man ^b   Tsao, Sai Wah ^b   Chan, Anthony Tak Cheung ^a,c  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Chk1 2 activation; Hypoxia selectivity; Hypoxia targeting; Nasopharyngeal carcinoma (NPC); Tirapazamine

Indexed keywords

CARBONATE DEHYDRATASE IX; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LATENT MEMBRANE PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ONCOPROTEIN; TIRAPAZAMINE; VASCULOTROPIN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL DIVISION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SELECTIVITY; ENZYME ACTIVATION; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; HYPOXIA; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; VIRUS GENOME;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NASOPHARYNGEAL NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; S PHASE; SIGNAL TRANSDUCTION; TRIAZINES; UP-REGULATION; VIRAL MATRIX PROTEINS;

EID: 79955585432     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-009-9356-z     Document Type: Article

References (52)

1. Brahimi-Horn MC, Chiche J, Pouyssegur J (2007) Hypoxia and cancer. J Mol Med 85:1301-1307 (Pubitemid 50004093)
2. Vaupel P (2008) Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist 13(Suppl 3):21-26
3. Vaupel P, Mayer A (2007) Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 26:225-239 (Pubitemid 47101660)
4. Dewhirst MW, Cao Y, Moeller B (2008) Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 8:425-437 (Pubitemid 351744964)
5. Cosse JP, Michiels C (2008) Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med Chem 8:790-797
6. Chan AT, Teo PM, Johnson PJ (2002) Nasopharyngeal carcinoma. Ann Oncol 13:1007-1015
7. Anderson KE, Mack TM, Silverman DT (2006) Cancer of the pancreas. In: Schottenfeld D, Fraumeni JF Jr (eds) Cancer epidemiology and prevention, 3rd edn. Oxford University Press, New York, pp 721-762
8. Yeh SH, Liu RS, Wu LC, Yang DJ, Yen SH, Chang CW, Yu TW, Chou KL, Chen KY (1996) Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma. Eur J Nucl Med 23:1378-1383 (Pubitemid 26340592)
9. Zheng YJ, Fan W, Zhao C, Yang XC, Cui NJ, Chen FJ (2006) Clinical application of 99mTc-HL91 hypoxia imaging in nasopharyngeal carcinoma. Ai Zheng 25:378-381
10. Zheng YJ, Zhao C, Fan W, Liu H, Cui NJ, Chen FJ (2007) Changes of hypoxia in primary lesion of nasopharyngeal carcinoma during the treatment course and the clinical value thereof. Zhonghua Yi Xue Za Zhi 87:2698-2702
11. Liu S, Xue Y, Zhang H, Liang JG, Lu XP, Liu XG, Chen SX, Jing NY (2007) Preliminary study on the value of 99Tc(m)-HL91 imaging in predicting sensitivity to radiotherapy in patients with nasopharyngeal carcinoma. Zhonghua Zhong Liu Za Zhi 29:369-372
12. Hui EP, Chan AT, Pezzella F, Turley H, To KF, Poon TC, Zee B, Mo F, Teo PM, Huang DP, Gatter KC, Johnson PJ, Harris AL (2002) Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 8:2595-2604 (Pubitemid 34856346)
13. Hui EP, Sung FL, Yu BK, Wong CS, Ma BB, Lin X, Chan A, Wong WL, Chan AT (2008) Plasma osteopontin, hypoxia, and response to radiotherapy in nasopharyngeal cancer. Clin Cancer Res 14:7080-7087
14. Sung FL, Hui EP, Tao Q, Li H, Tsui NB, Dennis Lo YM, Ma BB, To KF, Harris AL, Chan AT (2007) Genome-wide expression analysis using microarray identified complex signaling pathways modulated by hypoxia in nasopharyngeal carcinoma. Cancer Lett 253:74-88 (Pubitemid 46881199)
15. Jiang JH, Wang N, Li A, Liao WT, Pan ZG, Mai SJ, Li DJ, Zeng MS, Wen JM, Zeng YX (2006) Hypoxia can contribute to the induction of the Epstein-Barr virus (EBV) lytic cycle. J Clin Virol 37:98-103 (Pubitemid 44441974)
16. Li L, Lin X, Staver M, Shoemaker A, Semizarov D, Fesik SW, Shen Y (2005) Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res 65:7249-7258 (Pubitemid 41161256)
17. Robertson N, Potter C, Harris AL (2004) Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res 64:6160-6165 (Pubitemid 39129417)
18. Melillo G (2006) Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol Cancer Res 4:601-605
19. Nagle DG, Zhou YD (2006) Natural product-based inhibitors of hypoxia-inducible factor-1 (HIF-1). Curr Drug Targets 7:355-369 (Pubitemid 43744851)
20. Brown JM, Wilson WR (2004) Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4:437-447 (Pubitemid 38745529)
21. Shinde SS, Hay MP, Patterson AV, Denny WA, Anderson RF (2009) Spin trapping of radicals other than the *OH radical upon reduction of the anticancer agent tirapazamine by cytochrome P450 reductase. J Am Chem Soc 131:14220-14221
22. Brown JM (1999) The hypoxic cell: a target for selective cancer therapy-eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 59:5863-5870
23. Lartigau E, Guichard M (1995) Does tirapazamine (SR-4233) have any cytotoxic or sensitizing effect on three human tumour cell lines at clinically relevant partial oxygen pressure? Int J Radiat Biol 67:211-216
24. Siim BG, Menke DR, Dorie MJ, Brown JM (1997) Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia. Cancer Res 57:2922-2928 (Pubitemid 27315040)
25. Peters KB, Brown JM (2002) Tirapazamine: a hypoxia-activated topoisomerase II poison. Cancer Res 62:5248-5253 (Pubitemid 35024598)
26. Peters KB, Wang H, Brown JM, Iliakis G (2001) Inhibition of DNA replication by tirapazamine. Cancer Res 61:5425-5431 (Pubitemid 32694922)
27. Le QT, Moon J, Redman M, Williamson SK, Lara PN Jr, Goldberg Z, Gaspar LE, Crowley JJ, Moore DF Jr, Gandara DR (2009) Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222. J Clin Oncol 27:3014-3019
28. Rischin D, Peters L, Fisher R, Macann A, Denham J, Poulsen M, Jackson M, Kenny L, Penniment M, Corry J, Lamb D, McClure B (2005) Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans- Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol 23:79-87 (Pubitemid 41702625)
29. Aghajanian C, Brown C, O'Flaherty C, Fleischauer A, Curtin J, Roemeling R, Spriggs DR (1997) Phase I study of tirapazamine and cisplatin in patients with recurrent cervical cancer. Gynecol Oncol 67:127-130 (Pubitemid 27500406)
30. Bedikian AY, Legha SS, Eton O, Buzaid AC, Papadopoulos N, Coates S, Simmons T, Neefe J, von Roemeling R (1997) Phase II trial of tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma. Ann Oncol 8:363-367 (Pubitemid 27230977)
31. von Pawel J, von Roemeling R, Gatzemeier U, Boyer M, Elisson LO, Clark P, Talbot D, Rey A, Butler TW, Hirsh V, Olver I, Bergman B, Ayoub J, Richardson G, Dunlop D, Arcenas A, Vescio R, Viallet J, Treat J (2000) Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors. J Clin Oncol 18:1351-1359 (Pubitemid 30159856)
32. Wong JH, Lui VW, Umezawa K, Ho Y, Wong EY, Ng MH, Cheng SH, Tsang CM, Tsao SW, Chan AT (2009) A small molecule inhibitor of NF-kappaB, dehydroxymethylepoxyquinomicin (DHMEQ), suppresses growth and invasion of nasopharyngeal carcinoma (NPC) cells. Cancer Lett in press
33. Lui VW, Wong EY, Ho Y, Hong B, Wong SC, Tao Q, Choi GC, Au TC, Ho K, Yau DM, Ma BB, Hui EP, Chan AS, Tsang CM, Tsao SW, Grandis JR, Chan AT (2009) STAT3 activation contributes directly to Epstein-Barr virus-mediated invasiveness of nasopharyngeal cancer cells in vitro. Int J Cancer 125:1884-1893
34. Lui VW, Boehm AL, Koppikar P, Leeman RJ, Johnson D, Ogagan M, Childs E, Freilino M, Grandis JR (2007) Antiproliferative mechanisms of a transcription factor decoy targeting signal transducer and activator of transcription (STAT) 3: the role of STAT1. Mol Pharmacol 71:1435-1443 (Pubitemid 46658696)
35. Bartek J, Lukas C, Lukas J (2004) Checking on DNA damage in S phase. Nat Rev Mol Cell Biol 5:792-804 (Pubitemid 39336273)
36. Nagasawa H, Uto Y, Kirk KL, Hori H (2006) Design of hypoxiatargeting drugs as new cancer chemotherapeutics. Biol Pharm Bull 29:2335-2342 (Pubitemid 44885846)
37. Kondo S, Seo SY, Yoshizaki T, Wakisaka N, Furukawa M, Joab I, Jang KL, Pagano JS (2006) EBV latent membrane protein 1 upregulates hypoxia-inducible factor 1alpha through Siah1-mediated down-regulation of prolyl hydroxylases 1 and 3 in nasopharyngeal epithelial cells. Cancer Res 66:9870-9877 (Pubitemid 44672038)
38. Wakisaka N, Kondo S, Yoshizaki T, Murono S, Furukawa M, Pagano JS (2004) Epstein-Barr virus latent membrane protein 1 induces synthesis of hypoxia-inducible factor 1 alpha. Mol Cell Biol 24:5223-5234 (Pubitemid 38738158)
39. Janssen HL, Haustermans KM, Balm AJ, Begg AC (2005) Hypoxia in head and neck cancer: how much, how important? Head Neck 27:622-638 (Pubitemid 40961072)
40. Evans JW, Yudoh K, Delahoussaye YM, Brown JM (1998) Tirapazamine is metabolized to its DNA-damaging radical by intranuclear enzymes. Cancer Res 58:2098-2101 (Pubitemid 28232893)
41. Brown JM (2000) Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today 6:157-162
42. Falck J, Petrini JH, Williams BR, Lukas J, Bartek J (2002) The DNA damage-dependent intra-S phase checkpoint is regulated by parallel pathways. Nat Genet 30:290-294
43. Yang B, Reynolds CP (2005) Tirapazamine cytotoxicity for neuroblastoma is p53 dependent. Clin Cancer Res 11:2774-2780 (Pubitemid 40569480)
44. Nagasawa H, Yamashita M, Mikamo N, Shimamura M, Oka S, Uto Y, Hori H (2002) Design, synthesis and biological activities of antiangiogenic hypoxic cytotoxin, triazine-N-oxide derivatives. Comp Biochem Physiol A Mol Integr Physiol 132:33-40 (Pubitemid 34327729)
45. Wouters BG, Wang LH, Brown JM (1999) Tirapazamine: a new drug producing tumor specific enhancement of platinum-based chemotherapy in non-small-cell lung cancer. Ann Oncol 10(Suppl 5): S29-33
46. Sun Y, Hegamyer G, Cheng YJ, Hildesheim A, Chen JY, Chen IH, Cao Y, Yao KT, Colburn NH (1992) An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma. Proc Natl Acad Sci USA 89:6516-6520
47. Saunders MP, Patterson AV, Chinje EC, Harris AL, Stratford IJ (2000) NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line. Br J Cancer 82:651-656 (Pubitemid 30085204)
48. Shin HJ, Kim JY, Yoo CW, Roberts SA, Lee S, Choi SJ, Lee HY, Lee DH, Kim TH, Cho KH (2008) Carbonic anhydrase 9 (CA9) expression in tumor cells enhances sensitivity to tirapazamine. J Cancer Res Clin Oncol 134:397-404 (Pubitemid 351170062)
49. Skarsgard LD, Vinczan A, Skwarchuk MW, Chaplin DJ (1994) The effect of low pH and hypoxia on the cytotoxic effects of SR4233 and mitomycin C in vitro. Int J Radiat Oncol Biol Phys 29:363-367 (Pubitemid 24166547)
50. Skarsgard LD, Skwarchuk MW, Vinczan A, Chaplin DJ (1993) The effect of pH on the aerobic and hypoxic cytotoxicity of SR4233 in HT-29 cells. Br J Cancer 68:681-683 (Pubitemid 23301268)
51. Evans JW, Chernikova SB, Kachnic LA, Banath JP, Sordet O, Delahoussaye YM, Treszezamsky A, Chon BH, Feng Z, Gu Y, Wilson WR, Pommier Y, Olive PL, Powell SN, Brown JM (2008) Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells. Cancer Res 68:257-265 (Pubitemid 351380127)
52. Fitzsimmons SA, Lewis AD, Riley RJ, Workman P (1994) Reduction of 3-amino-1, 2, 4-benzotriazine-1, 4-di-N-oxide (tirapazamine, WIN 59075, SR 4233) to a DNA-damaging species: a direct role for NADPH:cytochrome P450 oxidoreductase. Carcinogenesis 15:1503-1510 (Pubitemid 24262132)